SEC Form 3 · accession 0000899243-17-012924
Eledon Pharmaceuticals, Inc. · ELDN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Keith Katkin
Director
Period of report
May 10, 2017
Accepted (ET)
May 11, 2017 · 8:25 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001404281
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | holding | — | — | — | 12,119 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F2,F1 | $19.76 | holding | — | — | — | — | Dec 29, 2025 | Common Stock | 5,363 | — | D |
Explanation of responses
- F1All numbers give effect to the 1:9 reverse stock split effected by the Company on May 11, 2017.
- F2This option represents a right to purchase a total of 5,363 shares of the Issuer's Common Stock one quarter of which became fully vested and exercisable on December 30, 2016, with the remaining 4,022.25 shares vesting in equal quarterly installments over the following three years.
Remarks
Exhibit List: Exhibit 24 - Power of Attorney.